These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

633 related items for PubMed ID: 18410436

  • 1. Urinary fibronectin as a predictor of a residual tumour load after transurethral resection of bladder transitional cell carcinoma.
    Li LY, Yang M, Zhang HB, Su XK, Xu WF, Chen Y, Shen ZJ, Gao X.
    BJU Int; 2008 Aug 05; 102(5):566-71. PubMed ID: 18410436
    [Abstract] [Full Text] [Related]

  • 2. Diagnosis of bladder cancer by analysis of urinary fibronectin.
    Menéndez V, Fernández-Suárez A, Galán JA, Pérez M, García-López F.
    Urology; 2005 Feb 05; 65(2):284-9. PubMed ID: 15708039
    [Abstract] [Full Text] [Related]

  • 3. Urinary hyaluronan as a marker for the presence of residual transitional cell carcinoma of the urinary bladder.
    Passerotti CC, Bonfim A, Martins JR, Dall'Oglio MF, Sampaio LO, Mendes A, Ortiz V, Srougi M, Dietrich CP, Nader HB.
    Eur Urol; 2006 Jan 05; 49(1):71-5. PubMed ID: 16310928
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of two new urinary tumor markers: bladder tumor fibronectin and cytokeratin 18 for the diagnosis of bladder cancer.
    Sánchez-Carbayo M, Urrutia M, González de Buitrago JM, Navajo JA.
    Clin Cancer Res; 2000 Sep 05; 6(9):3585-94. PubMed ID: 10999749
    [Abstract] [Full Text] [Related]

  • 5. The value of a second transurethral resection for T1 bladder cancer.
    Schwaibold HE, Sivalingam S, May F, Hartung R.
    BJU Int; 2006 Jun 05; 97(6):1199-201. PubMed ID: 16566814
    [Abstract] [Full Text] [Related]

  • 6. Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR.
    Orsola A, Cecchini L, Raventós CX, Trilla E, Planas J, Landolfi S, de Torres I, Morote J.
    BJU Int; 2010 Jan 05; 105(2):202-7. PubMed ID: 19558557
    [Abstract] [Full Text] [Related]

  • 7. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O, Khalifa A.
    J Urol; 2002 Aug 05; 168(2):465-9. PubMed ID: 12131289
    [Abstract] [Full Text] [Related]

  • 8. Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer?
    Divrik T, Yildirim U, Eroğlu AS, Zorlu F, Ozen H.
    J Urol; 2006 Apr 05; 175(4):1258-61. PubMed ID: 16515974
    [Abstract] [Full Text] [Related]

  • 9. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
    May M, Hakenberg OW, Gunia S, Pohling P, Helke C, Lübbe L, Nowack R, Siegsmund M, Hoschke B.
    Urology; 2007 Sep 05; 70(3):449-53. PubMed ID: 17688921
    [Abstract] [Full Text] [Related]

  • 10. Recurrence-free survival after radical cystectomy of patients downstaged by transurethral resection.
    Nielsen ME, Bastian PJ, Palapattu GS, Trock BJ, Schoenberg MP, Chan T, Rogers CG.
    Urology; 2007 Dec 05; 70(6):1091-5. PubMed ID: 18158024
    [Abstract] [Full Text] [Related]

  • 11. [The significance of urine cytology three consecutive days after transurethral resection as a predictor of superficial bladder cancer recurrence].
    Yumura Y, Takase K, Kato Y, Hamano A, Mikata K, Ogo Y, Noguchi S, Satomi Y.
    Hinyokika Kiyo; 2004 Mar 05; 50(3):171-6. PubMed ID: 15148768
    [Abstract] [Full Text] [Related]

  • 12. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
    Shariat SF, Herman MP, Casella R, Lotan Y, Karam JA, Stenman UH.
    Eur Urol; 2005 Sep 05; 48(3):424-31. PubMed ID: 15963628
    [Abstract] [Full Text] [Related]

  • 13. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
    Kunju LP, You L, Zhang Y, Daignault S, Montie JE, Lee CT.
    J Urol; 2008 Nov 05; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
    [Abstract] [Full Text] [Related]

  • 14. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder.
    Shariat SF, Matsumoto K, Casella R, Jian W, Lerner SP.
    Eur Urol; 2005 Jul 05; 48(1):69-76. PubMed ID: 15967254
    [Abstract] [Full Text] [Related]

  • 15. Impact of transurethral resection of bladder tumor: analysis of cystectomy specimens to evaluate for residual tumor.
    Lee SE, Jeong IG, Ku JH, Kwak C, Lee E, Jeong JS.
    Urology; 2004 May 05; 63(5):873-7; discussion 877. PubMed ID: 15134968
    [Abstract] [Full Text] [Related]

  • 16. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
    Kibar Y, Goktas S, Kilic S, Yaman H, Onguru O, Peker AF.
    Ann Clin Lab Sci; 2006 May 05; 36(1):31-8. PubMed ID: 16501234
    [Abstract] [Full Text] [Related]

  • 17. A second-look TUR in T1 transitional cell carcinoma: why?
    Jakse G, Algaba F, Malmström PU, Oosterlinck W.
    Eur Urol; 2004 May 05; 45(5):539-46; discussion 546. PubMed ID: 15082193
    [Abstract] [Full Text] [Related]

  • 18. Cellular fibronectin in patients with transitional cell carcinoma of the bladder.
    Hegele A, Heidenreich A, Varga Z, von Knobloch R, Olbert P, Kropf J, Hofmann R.
    Urol Res; 2003 Feb 05; 30(6):363-6. PubMed ID: 12599015
    [Abstract] [Full Text] [Related]

  • 19. Interleukin-6/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma.
    Cai T, Mazzoli S, Meacci F, Tinacci G, Nesi G, Zini E, Bartoletti R.
    J Urol; 2007 Nov 05; 178(5):1906-11;discussion 1911-2. PubMed ID: 17868727
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
    Nisman B, Barak V, Shapiro A, Golijanin D, Peretz T, Pode D.
    Cancer; 2002 Jun 01; 94(11):2914-22. PubMed ID: 12115379
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.